Natural Killer Cells Market Segmentation:
By Source
- NK-92 Cell Line
- Peripheral Blood NK Cells
- Umbilical Cord Blood NK Cells
- Induced Pluripotent Stem Cell-Derived NK Cells
- Embryonic Stem Cell-Derived NK Cells
By Type
- Cytokine-Induced Killer Cells
- Tumor-Infiltrating NK Cells
- Allogeneic NK Cells
- Autologous NK Cells
By Application
- Cancer Immunotherapy
- Infectious Diseases
- Immunoproliferative Disorders
- Others
By End User
- Hospitals
- Research Institutes
- Pharmaceutical Companies
- Biotech Companies
- Others
Frequently Asked Questions
The Natural Killer Cells market is estimated to be USD 0.559 million in 2023.
Rising cancer prevalence, advances in cell therapy manufacturing and genetic engineering of NK cells, investments into R&D, and increasing industry focus on development of off-the-shelf allogeneic NK cell therapies.
High costs involved in therapy manufacturing, stringent regulatory requirements, and short product lifespan.
Allogeneic NK cells owing to their logistical advantages and ability to be used as an off-the-shelf therapy.
Fate Therapeutics, Affimed N.V., Glycostem Therapeutics, Kiadis Pharma, Innate Pharma, Nkarta Therapeutics, and others.
The market is projected to reach USD 6.0 billion by 2031, growing at a CAGR of 34.5% from 2023 to 2031.
Increasing prevalence of cancer globally, growing R&D investments and pipeline of NK cell therapies, advances in cell engineering and processing technologies, logistical advantages of off-the-shelf products, and increased industry focus.